The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Open accessAbstract
Background Elevated lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS). Oxidized phospholipids (OxPL) are key mediators of calcification in valvular cells and are carried by Lp(a).Objectives This study sought to determine whether Lp(a) and OxPL are associated with hemodynamic progression of AS and AS-related events.Methods OxPL on apolipoprotein B-100 (OxPL-apoB), which reflects the biological activity of Lp(a), and Lp(a) levels were measured in 220 patients with mild-to-moderate AS. The primary endpoint was the progression rate of AS, measured by the annualized increase in peak aortic jet velocity in m/s/year by Doppler echocardiography; the secondary endpoint was need for aortic valve replacement and cardiac death during 3.5 ± 1.2 years of follow-up.Results AS progression was faster in patients in the top tertiles of Lp(a) (peak aortic jet velocity: +0.26 ± 0.26 vs. +0.17 ± 0.21 m/s/year; p = 0.005) and OxPL-apoB (+0.26 ± 0.26 m/s/year vs. +0.17 ± 0.21 m/s/year; p = 0.01). After multivariable adjustment, elevated Lp(a) or OxPL-apoB levels remained independent predictors of faster AS progression. After adjustment for age, sex, and baseline AS severity, patients in the top tertile of Lp(a) or OxPL-apoB had increased risk of aortic valve replacement and cardiac death.Conclusions Elevated Lp(a) and OxPL-apoB levels are associated with faster AS progression and need for aortic valve replacement. These findings support the hypothesis that Lp(a) mediates AS progression through its associated OxPL and provide a rationale for randomized trials of Lp(a)-lowering and OxPL-apoB-lowering therapies in AS. (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin [ASTRONOMER]; NCT00800800).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical factors associated with faster stenosis progression include older age, female sex, severity of the stenosis and degree of aortic valve calcification at diagnosis, smoking, hypertension, obesity, metabolic syndrome, secondary hyperparathyroidism, renal failure elevated circulating levels of Lp(a), and increased activity of Lp-PLA2 (also called lipoprotein–associated phospholipase A2)51”
From Calcific aortic stenosis (2016) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the presence of elevated plasma Lp(a) (>50 mg per dL; the upper normal limit is <30 mg per dL)) is associated with a twofold faster stenosis progression51.”
From Calcific aortic stenosis (2016) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, Capoulade and colleagues showed that circulating Lp(a) and Ox-PL levels were independently associated with faster progression of calcific AS51.”
From Calcific aortic stenosis (2016) · cites this paper as [51]
In the citing paper
“prior studies have linked ApoB to the onset and accelerated progression of CAVD [38,39].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,487
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Guidelines on the management of valvular heart disease
Vahanian, A. S., Baumgartner, H., Bax, J. J., Butchart, E., Dion, R., Filippatos, G. S., Flachskampf, F., Hall, R., Iung, B., Kasprzak, J. D., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl428 · Cited by 3,579
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000029 · Cited by 2,566
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O'Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.537 · Cited by 1,642
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Flagged first, then by citations
Research works printed but not linked: 1
- Tsimikas, 2015, Antisense therapy targeting apolipoprotein (a) reduces plasma lipoprotein(a) Levels, Lancet
Cited by
Sorted by citations
Items 301–400 of 417
Demer, L. L., & Tintut, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814661-3.00011-3 · Cited by 3
Mouriño-Álvarez, L., Martín-Rojas, T., Corros-Vicente, C., Corbacho-Alonso, N., Padial, L. R., Solı́s, J., & Barderas, M. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082421 · Cited by 3
Masson, W. M., Lobo, M., Barbagelata, L., Bagnati, R. P., OBERTI, P. F., Falconi, M. L., Krauss, J. G., PARCERISA, F., & Pizarro, R. (2022) · Revista Argentina de Cardiología · doi:10.7775/rac.v90.i3.20516 · Cited by 3
Precision Medicine for Prosthetic Valve Deterioration
Thanassoulis, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.065 · Cited by 3
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Capoulade, R., & Cariou, B. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.009 · Cited by 3
Self-citationBiomarkers Associated with Aortic Stenosis and Structural Bioprosthesis Dysfunction
Oury, C., Côté, N., & Clavel, M.-A. (2020) · Cardiology Clinics · doi:10.1016/j.ccl.2019.09.005 · Cited by 2
Prabutzki, P., Schiller, J., & Engel, K. M. (2025) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.5c00196 · Cited by 2
Ren, Y., & Deng, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05196-4 · Cited by 2
Li, Q., Xu, J., Xiong, Z., & Ying, Q. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112940 · Cited by 2
Jang, A. Y., Lee, J. H., Lee, S., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0388 · Cited by 2
Lipoprotein(a) and Aortic Valve Stenosis: From Pathophysiology to Emerging Pharmacological Agents
Agnello, F. G., Laterra, G., Scalia, L., Mauro, M. S., Strazzieri, O., Reddavid, C., Ingala, S., Guarino, S., Barbera, C., Russo, M. D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010274 · Cited by 2
Jang, A. Y., Lee, J. H., Lee, S.-G., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.2 · Cited by 2
Calcific Aortic Valve Disease: Mechanism and Future Therapeutic Strategies
Hwang, G., Jo, S., Kwon, H., Kwon, M., Ku, I., Song, J.-K., & Jo, Y. H. (2026) · Cells · doi:10.3390/cells15060542 · Cited by 2
Mansouri, P., & Vafa, R. G. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124371 · Cited by 4
Kuzo, N., Stähli, B. E., Erhart, L., Anwer, S., Schindler, M., Kebernik, J., Mathys, S., Nguyen‐Kim, T. D. L., Eberhard, M., Ruschitzka, F. T., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.030 · Cited by 2
Lipoprotein(a) and kidney diseases
Pyatchenkov, M. O., Rumyantsev, A. S., Владимирович, З. М., Sherbakov, E. V., & Belskykh, A. N. (2021) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2021-25-1-31-46 · Cited by 3
What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?
Tsimikas, S. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e7 · Cited by 2
Self-citationTserensonom, M., Yagi, S., Ise, T., Kawabata, Y., Kadota, M., Hara, T., Kusunos, K., Yamaguchi, K., Yamada, H., Soeki, T., et al. (2023) · The Journal of Medical Investigation · doi:10.2152/jmi.70.450 · Cited by 2
Elevated Lp(a): Guidance for Identifying and Managing Patients
Hilleman, D. E., Vacek, J. L., & Backes, J. M. (2024) · Southern Medical Journal · doi:10.14423/smj.0000000000001675 · Cited by 2
Prabhakar, A. P., & López‐Candales, A. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2406740 · Cited by 2
Kaltoft, M., Langsted, A., & Nordestgaard, B. G. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2022.2.e20 · Cited by 2
The year in cardiology 2015: prevention.
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016) · Cardiologia Croatica · doi:10.15836/ccar2016.218 · Cited by 2
Philippova, M., Oskolkova, O., & Bochkov, V. N. (2019) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201800511 · Cited by 2
Liu, J., Zhao, M., Zhu, Y., Zheng, L., & Yin, Y. (2020) · PROTEOMICS · doi:10.1002/pmic.202000050 · Cited by 2
Clavel, M.-A. A., Côté, N., & Pîbarot, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-23104-0_3 · Cited by 2
Lp(a) and risk of cardiovascular disease – A review of existing evidence and emerging concepts
Jasti, M., Islam, S., Steele, N., Ivy, K. N., Maimo, W., & Isiadinso, I. (2023) · Journal of the National Medical Association · doi:10.1016/j.jnma.2023.11.009 · Cited by 2
The Role of Lipoprotein(a) in Calcific Aortic Valve Disease
Garg, V. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4267 · Cited by 2
Tao, T., Zheng, J., Han, Y., Yang, Q., Ni, Y., & Ma, L. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s363989 · Cited by 1
Clinical Update on the Intersection of Lipoprotein(a) and Calcific Valve Disease
Ashley, S. C., Kachhy, E., Brown, K. A., Prescott, M. E., Kelsey, M. D., McGarrah, R. W., Pagidipati, N. J., & Shah, N. P. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00765-w · Cited by 1
Xiang, L., & Su, Z. (2025) · European journal of medical research · doi:10.1186/s40001-025-02927-3 · Cited by 3
Hartley, A., Williams, M. C., Kaura, A., Verhemel, S., Caga‐Anan, M., Dey, D., Dweck, M. R., Haskard, D. O., Joner, M., Mayr, M., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.041524 · Cited by 1
Pagnesi, M., Riccardi, M., Maisano, F., Antohi, E., Barberis, V. I., Hamid, M. A., Arfsten, H., Grapsa, J., Karam, N., Muraru, D., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf027 · Cited by 1
Decoding calcific aortic valve disease: superior predictive power of time-weighted lipoprotein(a)
Jiang, D., Liu, Y.-L., Liu, J., Wang, P., Chen, J.-L., Wen, X.-S., Liu, J., Gao, L., Li, D.-T., & Zhang, D.-Y. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02884-8 · Cited by 1
Shi, W., Han, H., Pei, J., Ding, C., Yao, Y., Zhang, H., Xu, H., Wu, Y. O. N. G. J. I., Li, Z. C., & Zhang, B. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag257 · Cited by 1
Lipidomic remodeling is associated with hemodynamic severity in calcific aortic valve stenosis
Surendran, A., Stamenković, A., Jassal, D. S., Shah, A., & Ravandi, A. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00960.2025 · Cited by 1
Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target
Epelde, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1908850 · Cited by 1
Editor-in-Chief’s Top Picks From 2015: Part One
Fuster, V. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.002 · Cited by 1
Place des marqueurs biologiques dans l’exploration du rétrécissement aortique calcifié
Varennes, O., Six, I., Mentaverri, R., & Kamel, S. (2017) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(17)30238-1 · Cited by 1
Tanaka, M., Nishimura, T., & Itoh, H. (2017) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000755
Lipoprotein(a)—It Is Risky, but What Do We Do About It?
Després, A.-A., & Arsenault, B. J. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0592-7 · Cited by 1
Self-citationGenetic Disorders of Lipoprotein Metabolism
Brown, A. S., Dababneh, E. G., Chaus, A. M., Chyzhyk, V., Marinescu, V., & Pyslar, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_3 · Cited by 1
Muhammad, A. (2022) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410271 · Cited by 1
Feistner, L., Penk, A., Böttner, J., Buttner, P. G., Thiele, H., Huster, D., & Schlotter, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-46143-7 · Cited by 2
Unraveling the Enigma of Moderate Aortic Stenosis: Challenges and Future Prospects
Santangelo, G., Tumminello, G., Barbieri, L., Mallardi, G. P. F., Faggiano, A., Moscardelli, S., Rossi, A., Cozza, F., Carugo, S., & Faggiano, P. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123478 · Cited by 1
Santangelo, G., Antonini‐Canterin, F., & Faggiano, P. M. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26537 · Cited by 1
Inflammation markers in coronary heart disease patients with aortic valve stenosis
Afanasieva, O. I., Tmoyan, N. A., Александровна, К. Е., Андреевна, Р. О., Afanasieva, M. I., Burdeynaya, A. L., Saidova, M. A., Владиславович, Е. М., & Pokrovsky, S. N. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-9-17-22 · Cited by 1
Prospective Advances in Non-coding RNAs Investigation
Jan, M. I., Ali, T., Ishtiaq, A., Mushtaq, I., & Murtaza, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1671-9_24 · Cited by 1
Oxidized lipid species in lipoproteins: Significance and analytical considerations
Shrestha, R., Chiba, H., & Hui, S. (2020) · doi:10.24508/mms.2020.06.003 · Cited by 1
Zavrtanik, M., Likozar, A. R., & Šebeštjen, M. (2021) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3057
Martinez, L. O., Perret, B., & Genoux, A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000771 · Cited by 1
In search of the smoking gun in calcific aortic valve disease
Murashita, T., & Badhwar, V. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.02.039 · Cited by 1
Lipoprotein(a): Solving the Puzzle, Deciphering the Riddle, Unraveling the Enigma
Thanassoulis, G. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.018 · Cited by 1
Lipoprotein (a): a promising target in the treatment of stenotic valvular diseases
Pîbarot, P., Rosenhek, R., & Lancellotti, P. (2016) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jew022
Godina 2015. u kardiologiji: prevencija The year in cardiology 2015: prevention
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016)
New Considerations in the Assessment of Aortic Stenosis
Safi, L. M., Passeri, J. J., & Picard, M. H. (2017) · Future Cardiology · doi:10.2217/fca-2017-0031
Osteocardiology: Calcific Aortic Valve Disease
Rajamannan, N. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-64994-8_3
Aortic stenosis from the perspective of the current guidelines
Jelavić, M. M., & Pintarić, H. (2019) · Rad Hrvatske akademije znanosti i umjetnosti Medicinske znanosti · doi:10.21857/yq32oh40d9
¿Qué debe saber el cardiólogo clínico sobre la lipoproteína (a)?
Machado, F., & Reyes, X. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.22
Lipoprotein (a): Principles from Bench to Bedside
Koschinsky, M. L., & Boffa, M. B. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_19
McNeal, C. J., & Peterson, A. L. H. (2020)
Editor-in-Chief’s Top Picks From 2015: Part Two
Fuster, V. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.003
Kaiser, Y., Nurmohamed, N. S., Stroes, E. S. G., & Boekholdt, S. M. (2022) · Heart · doi:10.1136/heartjnl-2021-320644
Santangelo, G., Bernardi, N., Faggiano, A., Bonelli, A., Toriello, F., Faggiano, P. M., & Carugo, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102902
Masson, W. M., Lobo, M., Barbagelata, L., Bagnati, R. P., OBERTI, P. F., Falconi, M. L., Krauss, J. G., Parcerisa, F., & Pizarro, R. (2022) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v90.i3.20516
Dong, Q., Zhang, Y., Zhou, K., & Zhang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1943662/v1
Lp(a): A New Star of Preventing Cardiovascular Events
漆, 晨. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121592
Lipoprotein(a) and Calcific Aortic Valve Stenosis
Kosmas, C. E., Silverio, D., Sourlas, A., Campos, F. N., Montan, P. D., & Guzman, E. (2019) · EMJ Cardiology · doi:10.33590/emjcardiol/10310024
Molecular Mechanisms of Lipoprotein(a) Pathogenicity: Tantalizing Clues and Unanswered Questions
Boffa, M. B., & Koschinsky, M. L. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_10
Aortic valve stenosis in familial hypercholesterolaemic: Should we systematically screen?
Lutun, J., Cohen, A. A., Eltchaninoff, H., & Boccara, F. (2023) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2023.05.001
Lipoprotein(a) in Cardiovascular Risk Assessment
Boffa, M. B., Koschinsky, M. L., & Marcovina, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00005-4
Understanding the driving mechanisms of bioprosthetic valve degeneration
Wachtell, K. (2023) · Heart · doi:10.1136/heartjnl-2023-323210
The influence of lipoproteina(a) on cardio-vascular diseases
Maj-Dziedzic, M., Brzozowska, A., Sikora, M., Zarzycka, M., Plewniok, I., Dubiel, J., Maj, A., Śmietana, G., Warno, M., & Kozik, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.54.013
Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities
Karp, A., Jacobs, M. M., Barris, B., Labkowsky, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000667
Mutithu, D. W., Aremu, O. O., Mokaila, D., Bana, T., Familusi, M. A., Taylor, L. J., Martin, L. J., Heathfield, L. J., Kirwan, J., Wiesner, L., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303496
Reiner, Ž., Miličić, D., Rogić, D., Manola, Š., Ružić, A., Canecki-Vražić, S., Kristić, I., Zulle, B.-L., Đerek, L., Šerić, V., et al. (2024) · Liječnički vjesnik · doi:10.26800/lv-146-1-2-7
Cui, J., Zhang, Y., Zhang, W., Li, D., Hong, Z., Zhao, L., Sun, J., Chen, Y., & Zhang, N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01218-2 · Cited by 1
Biologically Active Lipids in Vascular Biology
Upchurch, C. M., & Leitinger, N. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_9
Analysis of risk factors for aortic stenosis in patients with familial hypercholesterolemia
Korneva, V. A., & Kuznetsova, Т. Y. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6068
van der Meijden, R. H. M., Kuster, C., van Broekhoven, A., Allgayer, R., Rutten, L., Roverts, R., Cerruti, M., Macías‐Sánchez, E., Cornel, J. H., Sommerdijk, N. A. J. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.03.641198
Lipoproteina(a): fattore di rischio cardiovascolare tra clinica e laboratorio
Bonetti, G., & Carta, M. (2025) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.25.00279-8
The Process of Atheroma Growth, Vulnerability, and Rupture
Watanabe, T., & Fan, J. (2025) · Springer eBooks · doi:10.1007/978-981-96-3675-4_13
Unveiling Lipoprotein(a): A New Frontier in Heart Health
Tabowei, G., Parepalli, D., Sanders, T., Ogedegbe, O. J., Sukhera, A. B., Alugba, G., Dadzie, S., Modi, B., Mejulu, E. O., Reyes, L. G., et al. (2025) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636251341038
Алексеевна, М. О., Kokurina, D. A., Ryabikov, A. N., Semenova, I. A., Antonov, A. B., & Kudryavtsev, A. V. (2025) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20252002127
Aortic Valve Stenosis and Acute Coronary Syndrome. Obvious Answers to Non-Obvious Questions
Барбараш, О. Л., & Кашталап, В. В. (2025) · Kardiologiia · doi:10.18087/cardio.2025.5.n2886
Research Status of the Relationship between Lipoprotein(a) and Cardiovascular Diseases
陈, 安. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1561717
Does statin matter when it comes to Lipoprotein(a) levels?
Agouridis, A. P., Filippatos, T. D., Kostara, C. E., Kostapanos, M. S., & Tsimihodimos, V. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120466
Korneva, V. A., & Kuznetsova, Т. Y. (2025) · Новые Санкт-Петербургские врачебные ведомости. · doi:10.24884/1609-2201-2025-104-1-32-43
Risk Stratification of Patients With Moderate Aortic Stenosis Using Aortic Valve CalciumPreprint
Watson, H., Ahmad, S. R., Patel, K. N., Pîbarot, P., Leipsic, J. A., Awad, M. A., Balla, S., & Zeb, I. (2025) · medRxiv · doi:10.1101/2025.08.01.25332711
A little calcium goes a long way: rethinking early calcific aortic valve disease
Clavel, M.-A. A. (2025) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaf303
Ruder, S., Mansfield, B., Immelman, A., Varki, N. M., Miu, P., Raal, F. J., & Tsimikas, S. (2022) · Figshare · doi:10.6084/m9.figshare.21455936
Self-citationAntipenko, I. D., Stepanova, A., Shkurnikov, M. Y., Jeiran, K., Baranova, A., & Tonevitsky, A. (2025) · Progress in Lipid Research · doi:10.1016/j.plipres.2025.101375 · Cited by 1
Yang, S., Bai, Z., Ye, X., Mo, S., Chen, J., Zhang, M., Zhu, D., & Zhu, M. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-03952-x
Syryca, F., Krefting, J., Pellegrini, C., Rheude, T. A., Mayr, N. P., Salzmann, C., Starnecker, F., von Scheidt, M., Wolf, Z., Holdenrieder, S., et al. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-02909-3
Déterminants de la progression et de la réponse myocardique dans le rétrécissement aortique calcifié
Arangalage, D. (2018) · theses.fr (ABES) · doi:10.70675/cc101f7dz401ez4bc1zb308za377e4500f20
Le rôle de l'Epoxyde hydrolase soluble (sEH) dans la physiopathologie des calcifications vasculaires
Varennes, O. (2018) · theses.fr (ABES) · doi:10.70675/d554fcf1z9f51z419bz9693z571dd887124a
MicroARNs, marqueurs de la pathologie valvulaire aortique
Nader, J. (2019) · theses.fr (ABES) · doi:10.70675/4d490f42z8b44z4281zb256zd9d9d5976dab
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff
Metadata
- Authors
- Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., Witztum, J. L., Arsenault, B. J., Després, J.-P., Pibarot, P., & Tsimikas, S.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Ottawa Heart Institute (CA)
- University of California San Diego (US)
- St. Boniface Hospital (CA)
- McMaster University (CA)
- Corresponding author
- Tsimikas, Sotirios
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 66
- Issue
- 11
- Pages
- 1236-1246
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1609565130
- Cited by
- 417
- References
- 45
- Citations by year
- 2026: 26 · 2025: 49 · 2024: 37 · 2023: 37 · 2022: 52 · 2021: 30 · 2020: 40 · 2019: 47 · 2018: 26 · 2017: 38 · 2016: 32 · 2015: 3
- FWCI
- 24.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Corpus Université Laval (Université Laval) (submittedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- National Institutes of Health (HL055798, HL088093)
- University of California, San Diego
- Pfizer Canada
- Eli Lilly Canada
- Canadian Institutes of Health Research (MOP# 114997, MOP-245048, 114997, 245048)
- National Heart, Lung, and Blood Institute (HL-055798, HL093767, R01HL093767, HL119828, P01HL055798, R01HL119828, HL-088093, P01HL088093)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- aortic stenosis, calcific aortic stenosis, lipoprotein(a), oxidized phospholipids, apolipoprotein B-100, disease progression, aortic jet velocity, aortic valve replacement, cardiovascular mortality, valve calcification, Lp(a)-lowering therapy
- MeSH terms
- Adult, Aged, Aortic Valve, Aortic Valve Stenosis, Calcinosis, Death, Female, Humans, Male, Middle Aged, Oxidation-Reduction, Phospholipids, Ultrasonography, Biomarkers, Lipoprotein(a), Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
